Replies to post #138263 on Biotech Values

[DewDiligence]

These kinds of nuke patents are a dime a dozen, so I can’t imagine that the best case for IDIX is better than a tiny royalty.

If the USPTO interference had somehow advanced the business proposition for IDX184, that would've been a big deal, but it doesn't do that.